Crizotinib efficacy after progression with entrectinib in ROS1-Positive lung cancer: a case report

Basit Öğe Kaydı
dc.authoridSaadettin Kılıçkap / 0000-0003-1637-7390en_US
dc.authorscopusidSaadettin Kılıçkap / 8665552100en_US
dc.authorwosidSaadettin Kılıçkap / AAP-3732-2021en_US
dc.contributor.authorTaban, Hakan
dc.contributor.authorGüven, Deniz Can
dc.contributor.authorKılıçkap, Saadettin
dc.date.accessioned2022-11-11T08:08:58Z
dc.date.available2022-11-11T08:08:58Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractCrizotinib and entrectinib are approved tyrosine kinase inhibitors by the FDA to treat advanced-stage ROS1-positive non-small cell lung cancer (NSCLC). Although, entrectinib could be used after crizotinib, it is unknown whether crizotinib is effective after entrectinib. We report a case of NSCLC with ROS1 rearrangement that achieved a nearly complete response with crizotinib in the second-line treatment after progression with entrectinib. A 22-year-old Caucasian non-smoker female patient was diagnosed with stage IV non-squamous lung cancer with ROS1 positivity. We started on entrectinib as first-line therapy. Due to progression in the 10th month of treatment, entrectinib was stopped and crizotinib was started as a second -line treatment. At the end of the third month of the treatment, a nearly complete response was obtained in the follow-up imaging. The patient is still being followed up with crizotinib and is in the 15th month of treatment. Based on our experience, crizotinib can be an option as second-line therapy in patients who are treated with entrectinib in the first line, especially in patients without brain metastasis.en_US
dc.identifier.citationTaban, H., Guven, D. C., & Kılıçkap, S. (2022). Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case Report. Cureus, 14(8).en_US
dc.identifier.doi10.7759/cureus.27828en_US
dc.identifier.issue8en_US
dc.identifier.urihttps://doi.org/10.7759/cureus.27828
dc.identifier.urihttps://hdl.handle.net/20.500.12713/3321
dc.identifier.volume14en_US
dc.identifier.wosWOS:000861143700023en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKılıçkap, Saadettin
dc.language.isoenen_US
dc.publisherCUREUS INCen_US
dc.relation.ispartofCUREUS JOURNAL OF MEDICAL SCIENCEen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectTargeted Therapyen_US
dc.subjectLung Canceren_US
dc.subjectRos1en_US
dc.subjectEntrectiniben_US
dc.subjectCrizotiniben_US
dc.titleCrizotinib efficacy after progression with entrectinib in ROS1-Positive lung cancer: a case reporten_US
dc.typeArticleen_US

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu